Suppr超能文献

诱变研究揭示了人类A2A腺苷受体与生物胺G蛋白偶联受体之间的结构-活性相似性。

Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.

作者信息

Jiang Q, Lee B X, Glashofer M, van Rhee A M, Jacobson K A

机构信息

Molecular Recognition Section, NIDDK, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

J Med Chem. 1997 Aug 1;40(16):2588-95. doi: 10.1021/jm970084v.

Abstract

Structure-affinity relationships for ligand binding at the human A2A adenosine receptor have been probed using site-directed mutagenesis in the transmembrane helical domains (TMs). The mutant receptors were expressed in COS-7 cells and characterized by binding of the radioligands [3H]CGS21680, [3H]NECA, and [3H]XAC. Three residues, at positions essential for ligand binding in other G protein-coupled receptors, were individually mutated. The residue V(3.32) in the A2A receptor that is homologous to the essential aspartate residue of TM3 in the biogenic amine receptors, i.e., V84(3.32), may be substituted with L (present in the A3 receptor) but not with D (in biogenic amine receptors) or A. H250(6.52), homologous to the critical N507 of rat m3 muscarinic acetylcholine receptors, may be substituted with other aromatic residues or with N but not with A (Kim et al. J. Biol. Chem. 1995, 270, 13987-13997). H278(7.43), homologous to the covalent ligand anchor site in rhodopsin, may not be substituted with either A, K, or N. Both V84L(3.32) and H250N(6.52) mutant receptors were highly variable in their effect on ligand competition depending on the structural class of the ligand. Adenosine-5'-uronamide derivatives were more potent at the H250N(6.52) mutant receptor than at wild type receptors. Xanthines tended to be close in potency (H250N(6.52)) or less potent (V84L(3.32)) than at wild type receptors. The affinity of CGS21680 increased as the pH was lowered to 5.5 in both the wild type and H250N(6.52) mutant receptors. Thus, protonation of H250(6.52) is not involved in this pH dependence. These data are consistent with a molecular model predicting the proximity of bound agonist ligands to TM3, TM5, TM6, and TM7.

摘要

利用跨膜螺旋结构域(TMs)中的定点突变技术,对人A2A腺苷受体上配体结合的结构 - 亲和力关系进行了研究。突变受体在COS - 7细胞中表达,并通过放射性配体[3H]CGS21680、[3H]NECA和[3H]XAC的结合进行表征。对其他G蛋白偶联受体中配体结合至关重要的三个位点的残基进行了单独突变。A2A受体中与生物胺受体TM3中的必需天冬氨酸残基同源的残基V(3.32),即V84(3.32),可用L(存在于A3受体中)取代,但不能用D(在生物胺受体中)或A取代。与大鼠m3毒蕈碱型乙酰胆碱受体的关键N507同源的H250(6.52),可用其他芳香族残基或N取代,但不能用A取代(Kim等人,《生物化学杂志》,1995年,270卷,13987 - 13997页)。与视紫红质中共价配体锚定位点同源的H278(7.43),不能用A、K或N取代。根据配体的结构类别,V84L(3.32)和H250N(6.52)突变受体对配体竞争的影响差异很大。腺苷 - 5'-脲酰胺衍生物在H250N(6.52)突变受体上比在野生型受体上更有效。黄嘌呤类化合物在H250N(6.52)突变受体上的效力与野生型受体相近(H250N(6.52))或更低(V84L(3.32))。在野生型和H250N(6.52)突变受体中,随着pH降至5.5,CGS21680的亲和力均增加。因此,H250(6.52)的质子化与这种pH依赖性无关。这些数据与预测结合的激动剂配体与TM3、TM5、TM6和TM7接近的分子模型一致。

相似文献

引用本文的文献

5
Deciphering the Agonist Binding Mechanism to the Adenosine A1 Receptor.解析激动剂与腺苷A1受体的结合机制。
ACS Pharmacol Transl Sci. 2021 Jan 21;4(1):314-326. doi: 10.1021/acsptsci.0c00195. eCollection 2021 Feb 12.
6
A Adenosine Receptors: Protective vs. Damaging Effects Identified Using Novel Agonists and Antagonists.A 腺苷受体:使用新型激动剂和拮抗剂确定的保护作用与损伤作用
Drug Dev Res. 1998 Nov-Dec;45(3-4):113-124. doi: 10.1002/(SICI)1098-2299(199811/12)45:3/4<113::AID-DDR5>3.0.CO;2-S. Epub 1999 Mar 1.

本文引用的文献

2
Molecular Architecture of G Protein-Coupled Receptors.G蛋白偶联受体的分子结构
Drug Dev Res. 1996 Jan 1;37(1):1-38. doi: 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验